Wellcebro 100 Capsule contains Acebrophylline 100 mg, a bronchodilator and mucolytic agent primarily indicated for the management of respiratory conditions characterized by bronchospasm and excessive mucus production, such as chronic obstructive pulmonary disease (COPD), asthma, and bronchitis. Acebrophylline exerts its therapeutic effect by relaxing the smooth muscles of the bronchial airways, thereby facilitating easier airflow and improving respiratory function. Additionally, it enhances mucociliary clearance by reducing mucus viscosity and promoting expectoration, which aids in the removal of secretions from the respiratory tract. Wellcebro 100 Capsule is typically prescribed as an adjunct to conventional therapy to alleviate symptoms such as wheezing, shortness of breath, and persistent cough. The medication is generally well-tolerated, with a favorable safety profile; however, patients should be monitored for potential side effects including gastrointestinal disturbances, headache, or hypersensitivity reactions. It is contraindicated in individuals with known hypersensitivity to Acebrophylline or related xanthine derivatives. Dosage and duration of treatment should be individualized based on the severity of the condition and patient response. Wellcebro 100 Capsule should be used under medical supervision, with caution advised in patients with cardiac or renal impairment.